The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
RA is a common autoimmune disease that causes joint damage.It is necessary to reach the
standard as soon as possible and give effective drugs according to the patient's disease
activity to avoid disability. Tofacitinib(TF) is a new type of oral tyrosine kinase inhibitor
(JAKi) for the treatment of moderate to severe active RA. However, there is alack of Chinese
data on the joint scheme, long-term use, maintenance and stop of TF in the real world. We
will use the new JAK combination regimen to treat RA patients, and carry out long-term
clinical follow-up for 30 weeks.